Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : [68Ga]FAPI-46
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SOFIE Submits Investigational New Drug Application to US FDA for Pancreatic Cancer Imaging
Details : [68Ga]FAPI-46 is the Gallium-68 radiolabeled PET tracer consisting of FAPI -46 precursor small molecule critical drug intermediate consisting of a FAPI moiety conjugated with a DOTA chelator.
Brand Name : [68Ga]FAPI-46
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2021
Lead Product(s) : [68Ga]FAPI-46
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?